The VA has long been a leader in #cvCoag care. See how rapidly they adopted a population health approach to #AntithromboticStewardship in this @CircOutcomes article. Thanks to @AHRQNews for funding! https://t.co/nengGSopT9
1/📌New Paper✏️
Prior work has shown convincingly that there are racial disparities in access to #LVAD and txp for pts with adv HF.
We sought to understand if inequities exist among pts receiving care at expert centers & if pt preferences for care would impact disparities
Amiodarone is an old anti-arrhythmic agent which means it can effect your LFTs, PFTs, and TFTs but not your NFTs because it's old and doesn't understand what they are.
Excited to see our paper in Annals today looking at blood pressure control regiments by adding multiple low dose meds vs. maxing dose then starting new meds. 🧵 https://t.co/3d4L2nZO4v
Excited to share our new #afib#screening decision model in @JAHA_AHA! Simulating 50m US individuals aged ≥65 years, we found 10 #afib screening strategies--including #wearables--were effective & minimized false positives. A fun @MGHHeartHealth & @mgh_ita collaboration.
🧵⬇️
The STROKESTOP trial and The LOOP study used different approaches to screen for #AtrialFibrillation, with the aim of initiating oral anticoagulation to prevent stroke and death https://t.co/Tmkr7gXJ6W @EmmaSvennberg, @johanengdahl2